Complete financial analysis of Inter & Co, Inc. (INTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inter & Co, Inc., a leading company in the Banks – Regional industry within the Financial Services sector.
- Daiwa Securities Group Inc. (8601.T) Income Statement Analysis – Financial Results
- American Metals Recovery and Recycling Inc. (AMRR) Income Statement Analysis – Financial Results
- FirstGroup plc (FGP.L) Income Statement Analysis – Financial Results
- Japan Asia Investment Co., Ltd. (8518.T) Income Statement Analysis – Financial Results
- BurgerFi International, LLC (BFIIW) Income Statement Analysis – Financial Results
Inter & Co, Inc. (INTR)
About Inter & Co, Inc.
Inter & Co, Inc., through its subsidiaries, engages in the banking, securities, insurance brokerage, marketplace, asset management, and services businesses. The company's Banking segment offers banking products and services, including checking accounts, cards, deposits, loans and advances, and other services. Its Securities segment provides services relating to the purchase, sale, and custody of securities; and portfolio management, as well as the establishment, organization, and management of investment funds. The company's Insurance Brokerage segment offers life, property, auto, financial, lost or stolen credit card, dental, warranties, travel, and credit protection insurance products. Its Marketplace segment operates a digital platform that offer goods and/or services to its customers. The company's Asset Management segment is involved in the operations related to the management of fund portfolios and other assets. Its Services segment provides services in the collection and management of personal information; development and licensing of customized and non-customized computer programs; and technical support, maintenance, and other information technology services. The company was founded in 1994 and is based in Belo Horizonte, Brazil.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.21B | 3.56B | 2.58B | 1.14B | 753.67M | 471.55M | 295.87M | 272.70M | 249.44M | 106.35M | 85.22M | 123.33M |
| Cost of Revenue | -4.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.85B | 3.56B | 2.58B | 1.14B | 753.67M | 471.55M | 295.87M | 272.70M | 249.44M | 106.35M | 85.22M | 123.33M |
| Gross Profit Ratio | 244.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.12B | 2.05B | 1.14B | 677.18M | 410.92M | 232.16M | 172.26M | 137.32M | 113.02M | 39.37M | 53.58M | 100.84M |
| Selling & Marketing | 93.51M | 137.94M | 145.86M | 55.37M | 40.27M | 29.32M | 16.18M | 5.77M | 4.07M | 4.94M | 4.30M | 3.89M |
| SG&A | 2.41B | 2.19B | 1.29B | 732.55M | 451.19M | 261.48M | 188.44M | 143.10M | 117.09M | 90.20M | 77.86M | 120.13M |
| Other Expenses | 0.00 | -3.95B | 811.73M | 309.73M | 152.91M | 205.00K | 30.53M | 27.68M | 28.11M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.41B | -1.77B | 2.10B | 1.04B | 604.10M | 352.21M | 218.97M | 170.78M | 145.21M | 80.39M | 67.47M | 105.79M |
| Cost & Expenses | 2.41B | -1.77B | 2.10B | 1.04B | 604.10M | 352.21M | 218.97M | 170.78M | 145.21M | 80.39M | 67.47M | 105.79M |
| Interest Income | 6.16B | 4.27B | 2.18B | 951.17M | 841.90M | 636.39M | 497.23M | 577.70M | 480.48M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.89B | 1.97B | 587.59M | 235.46M | 255.68M | 217.28M | 276.43M | 320.84M | 237.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 160.44M | 163.97M | 94.25M | 43.66M | 17.46M | 2.61M | 1.38M | 1.28M | 3.33M | -27.59M | -16.02M | -13.82M |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.63M | 1.73M | 3.72M |
| EBITDA Ratio | 0.00% | 55.05% | 1.93% | -1.71% | 12.53% | 66.10% | 111.53% | 128.60% | 114.18% | -1.53% | 2.03% | 3.02% |
| Operating Income | 798.47M | 1.80B | -58.98M | -61.86M | 80.42M | 309.07M | 328.59M | 349.42M | 281.47M | 27.59M | 16.02M | 13.82M |
| Operating Income Ratio | 24.87% | 50.45% | -2.29% | -5.40% | 10.67% | 65.54% | 111.06% | 128.14% | 112.84% | 25.94% | 18.80% | 11.20% |
| Total Other Income/Expenses | -358.63M | -265.97M | -155.55M | 99.29M | -63.82M | -35.61M | -37.60M | -36.81M | -15.67M | -1.63M | 1.73M | 3.72M |
| Income Before Tax | 439.84M | -178.57M | -28.91M | -49.09M | 83.11M | 93.88M | 52.76M | 29.06M | 45.28M | 25.96M | 17.75M | 17.54M |
| Income Before Tax Ratio | 13.70% | -5.01% | -1.12% | -4.29% | 11.03% | 19.91% | 17.83% | 10.66% | 18.15% | 24.41% | 20.83% | 14.22% |
| Income Tax Expense | 87.58M | -164.49M | -93.61M | -54.67M | 1.54M | 24.05M | 5.08M | 3.23M | 11.58M | 3.80M | 615.00K | 1.30M |
| Net Income | 302.34M | -14.08M | 64.70M | 5.58M | 78.88M | 67.74M | 47.08M | 25.36M | 32.90M | 22.16M | 17.14M | 16.24M |
| Net Income Ratio | 9.42% | -0.40% | 2.51% | 0.49% | 10.47% | 14.37% | 15.91% | 9.30% | 13.19% | 20.84% | 20.11% | 13.17% |
| EPS | 0.75 | -0.04 | 0.24 | 0.01 | 0.04 | 0.78 | 0.35 | 0.01 | 0.01 | 0.10 | 0.08 | 0.08 |
| EPS Diluted | 0.75 | -0.04 | 0.24 | 0.01 | 0.04 | 0.78 | 0.34 | 0.01 | 0.01 | 0.10 | 0.08 | 0.08 |
| Weighted Avg Shares Out | 401.77M | 401.16M | 266.24M | 764.44M | 705.18M | 87.10M | 137.59M | 2.57B | 2.57B | 213.31M | 212.61M | 213.42M |
| Weighted Avg Shares Out (Dil) | 401.77M | 401.16M | 266.24M | 764.44M | 705.18M | 87.10M | 141.64M | 2.57B | 2.57B | 213.31M | 212.61M | 213.42M |
Lors de l'ASCO21, les données du portefeuille oncologique de Merck soulignent des avancées significatives dans le traitement du cancer
Source: https://incomestatements.info
Category: Stock Reports